< Back to previous page
Researcher
Diether Lambrechts
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Diether Lambrechts (KU Leuven)
Affiliations
- Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Lambrechts Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 2003 → 30 Sep 2005 - Department of Cellular and Molecular Medicine (Department)
Member
From1 Oct 1999 → 30 Sep 2003
Projects
1 - 7 of 7
- EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapyFrom1 Jan 2023 → TodayFunding: HORIZON.1.1 - European Research Council (ERC)
- VIB Grant for Lambrechts Lab_Period:2022-01-01-2026-12-31From1 Jan 2022 → TodayFunding: FRI - Project driven research
- CIRCULATING TUMOR DNA AS AN EPIGENETIC BIOMARKER FOR TUMOR RESPONSE’ — ‘INITIATOR’ - ERC POCFrom1 Aug 2020 → 31 Jan 2022Funding: HORIZON.1.1 - European Research Council (ERC)
- RESISTANCE UNDER COMBINATORIAL TREATMENT IN ER+ AND ER- BREAST CANCER.’ — ‘RESCUER’From1 Jan 2020 → TodayFunding: Other EU initiatives out of framework
- 'Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions’ — ‘COLOSSUS’From1 Jan 2018 → 31 Dec 2022Funding: Other EU initiatives out of framework
- Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics (GLIOTRAIN) - Marie Sklodowska-Curie actions (ITN)From1 Sep 2017 → 31 Aug 2021Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- VIB Grant for Lambrechts Lab_Period:2017-01-01-2021-12-31From1 Jan 2017 → 31 Dec 2021Funding: FRI - Project driven research
Publications
31 - 40 of 230
- PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.(2023)
Authors: Bram Boeckx, Diether Lambrechts
Pages: 131-139 - Obesity-associated changes in molecular biology of primary breast cancer.(2023)
Authors: Ayse Bassez, Diether Lambrechts
Pages: 4418 - Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors.(2023)
Authors: Bram Boeckx, Diether Lambrechts
Pages: 4341 - A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-?B signaling.(2023)
Authors: Patricia Altea Manzano, Ginevra Doglioni, Alejandro Cuadros, Juan Fernandez Garcia, Qi Wu, Xiaozheng Liu, Oskar Marin Bejar, Sofie Demeyer, Margherita Demicco, Hamza Furkan Alkan, et al.
Pages: 344-364 - Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.(2023)
Authors: Gonca Dilcan Durdag, Francesca Lodi, Diether Lambrechts
Pages: 327-338 - CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.(2023)
Authors: Diether Lambrechts
Pages: 697-713 - Organoids from human tooth showing epithelial stemness phenotype and differentiation potential.(2022)
Authors: Diether Lambrechts
Pages: 153 - Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study.(2022)
Authors: Diether Lambrechts
Pages: 1157-1170 - Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.(2022)
Authors: Bram Boeckx, Sam Vanmassenhove, Diether Lambrechts
Pages: 1147-1159 - Timing evolution of lobular breast cancer through phylogenetic analysis.(2022)
Authors: Bram Boeckx, Diether Lambrechts
Pages: 104169
Patents
1 - 10 of 10
- DISEASE DETECTION IN LIQUID BIOPSIES (Inventor)
- BIOMARKERS PREDICTING RESPONSE OF BREAST CANCER TO IMMUNOTHERAPY (Inventor)
- DISEASE DETECTION IN LIQUID BIOPSIES (Inventor)
- PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH AGE-RELATED DNA METHYLATION (Inventor)
- PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH AGE-RELATED DNA METHYLATION (Inventor)
- RETROTRANSPOSON BIOMARKERS (Inventor)
- RETROTRANSPOSON BIOMARKERS (Inventor)
- DISEASE DETECTION IN LIQUID BIOPSIES (Inventor)
- DETECTION OF OVARIAN CANCER IN LIQUID BIOPSIES (Inventor)
- PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH AGE-RELATED DNA METHYLATION (Inventor)